You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Targeted at drug development and clinical trials, the firm's new system allows the simultaneous collection of single-cell DNA and surface protein data.
Bluestar hopes to launch a pan-cancer, DNA methylation-based liquid biopsy assay as a laboratory-developed test out of an envisioned CLIA-certified lab in San Diego.
Green and his NHGRI colleagues published a strategic vision for human genomics research, emphasizing data science, implementation of genomics, and human diversity.
The firm's CLIA lab presented data at the virtual ASHG meeting showing how it validated WGS-based STR expansion analysis to diagnose rare disease.
Since the mutations are only found in a subset of patients' blood cells, the disorder, called VEXAS, might be treatable with a bone marrow transplant.
The company's acquisitions of Thrive Early Detection and Base Genomics are meant to accelerate its development of a liquid biopsy multi-cancer screening test.
A group of 11 labs around the world found that use of a QA/QC process allowed them to collect highly reproducible DIA proteomic data across sites.
Synthego has developed an off switch for CRISPR by engineering a guide RNA that can be controlled through exposure to UV light.
A recent study showed that a method called affine transformation can be used to increase the number of true positive qPCR samples detected.
The company recently received FDA Emergency Use Authorization for its SARS-CoV-2 PCR test while its data-driven COVID-19 research initiative is moving along.
Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.
The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.
The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.
In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.